Novartis AG ADR (NVS)vsTG Therapeutics Inc (TGTX)
NVS
Novartis AG ADR
$161.93
+0.38%
HEALTHCARE · Cap: $303.67B
TGTX
TG Therapeutics Inc
$59.83
+3.18%
HEALTHCARE · Cap: $8.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 7075% more annual revenue ($57.36B vs $799.54M). TGTX leads profitability with a 55.2% profit margin vs 17.5%. TGTX appears more attractively valued with a PEG of 1.61. TGTX earns a higher WallStSmart Score of 56/100 (C).
NVS
Hold48
out of 100
Grade: D+
TGTX
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$161.93
$66.37 premium
Intrinsic value data unavailable for TGTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Every $100 of equity generates 79 in profit
Keeps 55 of every $100 in revenue as profit
Revenue surging 70.3% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Trading at 14.0x book value
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : TGTX
The strongest argument for TGTX centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 55.2% and operating margin at 9.0%. Revenue growth of 70.3% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : TGTX
The primary concerns for TGTX are PEG Ratio, Price/Book, Debt/Equity.
Key Dynamics to Monitor
NVS profiles as a value stock while TGTX is a growth play — different risk/reward profiles.
TGTX carries more volatility with a beta of 1.80 — expect wider price swings.
TGTX is growing revenue faster at 70.3% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
TGTX scores higher overall (56/100 vs 48/100), backed by strong 55.2% margins and 70.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →TG Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?